Pharmasset
Setback for Gilead hep C candidate
February 20, 2012Research and Development, Sales and Marketing ELECTRON, GS-7977, Gilead, Pharmasset
Gilead’s investigational hepatitis C drug has been dealt a blow after patients suffer relapses in a mid-stage trial. In the …
Gilead aims for hep C lead with Pharmasset acquisition
November 22, 2011Research and Development Gilead, HCV, Pharmasset, Victrelis, hepatitis C
Gilead Sciences is to buy Pharmasset for $11 billion in a bid to become a leader in hepatitis C treatment.The …
Contract research news in brief
January 5, 2011Research and Development Accel Synthesis, Almac, Bioanalytical Systems, Caliper Life Sciences, Cambridge Research & Instrumentation, Critical Path Services, Pharmasset, ReSearch Pharmaceutical Services, ResourcingPoint, Warburg Pincus
Private equity firm Warburg Pincus buys RPS for $227 million, plus updates from BASi, Almac, Caliper, and Critical Path Services/Accel …
Latest content
Jennings becomes President of Beckman Coulter Diagnostics
October 19, 2026
Boyds expands Regulatory Affairs team to support growing demand
October 16, 2026
Sterling doubles ADC manufacturing capacity at Welsh facility
October 16, 2026
Femtosecond laser cuts lung tumour margin assessment time
October 15, 2026
